Literature DB >> 1689299

Heparin-binding growth factor-1 stimulation of human endothelial cells induces platelet-derived growth factor A-chain gene expression.

C G Gay1, J A Winkles.   

Abstract

Heparin-binding growth factor-1 (HBGF-1), also known as acidic fibroblast growth factor, is a potent mitogen for a variety of cell types including vascular endothelial and smooth muscle cells. Studies using murine 3T3 fibroblasts have shown that HBGF-1 induces numerous cellular responses such as the tyrosine phosphorylation of specific polypeptides and the increased expression of actin mRNA. Here we report that the addition of HBGF-1 to quiescent human umbilical vein endothelial cells increases the level of platelet-derived growth factor (PDGF) A-chain mRNA but not PDGF B-chain mRNA. In contrast, factors that inhibit endothelial cell proliferation such as phorbol myristate acetate and the cytokines interleukin-1, interleukin-6, and tumor necrosis factor-alpha increase both PDGF A-chain and B-chain mRNA levels. HBGF-1 induction of PDGF A-chain mRNA expression occurs in the presence of the protein synthesis inhibitor cycloheximide and thus does not require de novo protein synthesis. HBGF-1 also increases c-fos, c-jun, and c-myc mRNA levels; in the presence of cycloheximide, PDGF A-chain and protooncogene mRNA accumulation kinetics are similar. Nuclear run-on experiments indicate that the transcription rate of the PDGF A-chain gene transiently increases after HBGF-1 addition. Immunoprecipitation analysis using PDGF A-chain-specific antibodies indicates that HBGF-1-stimulated cells synthesize and secrete an increased amount of PDGF relative to unstimulated cells. If HBGF-1 can regulate PDGF expression by vascular endothelial cells in vivo, then HBGF-1 availability would be an important component of smooth muscle cell growth control. For example, HBGF-1 within the vessel wall would promote smooth muscle cell proliferation by (a) direct interaction with smooth muscle cell HBGF-1 receptors, and (b) increasing the amount of endothelial cell-derived PDGF available for binding to smooth muscle cell PDGF receptors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689299

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

Review 1.  Angiogenesis and vasculogenesis in treatment of cardiovascular disease.

Authors:  A Rivard; J M Isner
Journal:  Mol Med       Date:  1998-07       Impact factor: 6.354

2.  Acidic fibroblast growth factor promotes vascular repair.

Authors:  T D Bjornsson; M Dryjski; J Tluczek; R Mennie; J Ronan; T N Mellin; K A Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

3.  Interleukin 1 regulates heparin-binding growth factor 2 gene expression in vascular smooth muscle cells.

Authors:  C G Gay; J A Winkles
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-01       Impact factor: 11.205

4.  Time course of increased cellular proliferation in collateral arteries after administration of vascular endothelial growth factor in a rabbit model of lower limb vascular insufficiency.

Authors:  S Takeshita; S T Rossow; M Kearney; L P Zheng; C Bauters; S Bunting; N Ferrara; J F Symes; J M Isner
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

5.  Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue.

Authors:  W H Burgess; A M Shaheen; M Ravera; M Jaye; P J Donohue; J A Winkles
Journal:  J Cell Biol       Date:  1990-11       Impact factor: 10.539

6.  FGF-1-dependent proliferative and migratory responses are impaired in senescent human umbilical vein endothelial cells and correlate with the inability to signal tyrosine phosphorylation of fibroblast growth factor receptor-1 substrates.

Authors:  S Garfinkel; X Hu; I A Prudovsky; G A McMahon; E M Kapnik; S D McDowell; T Maciag
Journal:  J Cell Biol       Date:  1996-08       Impact factor: 10.539

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.